A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Jul 2016 Status changed from active, no longer recruiting to completed.
- 28 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Planned End Date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.